SMT202100055T1 - Anticorpi tau umanizzati nella malattia di alzheimer - Google Patents

Anticorpi tau umanizzati nella malattia di alzheimer

Info

Publication number
SMT202100055T1
SMT202100055T1 SM20210055T SMT202100055T SMT202100055T1 SM T202100055 T1 SMT202100055 T1 SM T202100055T1 SM 20210055 T SM20210055 T SM 20210055T SM T202100055 T SMT202100055 T SM T202100055T SM T202100055 T1 SMT202100055 T1 SM T202100055T1
Authority
SM
San Marino
Prior art keywords
alzheimer
disease
tau antibodies
humanized tau
humanized
Prior art date
Application number
SM20210055T
Other languages
English (en)
Inventor
Michal Novak
Eva Kontsekova
Branislav Kovacech
Rostislav Skrabana
Original Assignee
Axon Neuroscience Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axon Neuroscience Se filed Critical Axon Neuroscience Se
Publication of SMT202100055T1 publication Critical patent/SMT202100055T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7047—Fibrils-Filaments-Plaque formation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
SM20210055T 2014-11-19 2015-11-18 Anticorpi tau umanizzati nella malattia di alzheimer SMT202100055T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462081809P 2014-11-19 2014-11-19
EP15837211.0A EP3221349B1 (en) 2014-11-19 2015-11-18 Humanized tau antibodies in alzheimer's disease
PCT/IB2015/002610 WO2016079597A1 (en) 2014-11-19 2015-11-18 Humanized tau antibodies in alzheimer's disease

Publications (1)

Publication Number Publication Date
SMT202100055T1 true SMT202100055T1 (it) 2021-03-15

Family

ID=55411706

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20210055T SMT202100055T1 (it) 2014-11-19 2015-11-18 Anticorpi tau umanizzati nella malattia di alzheimer

Country Status (24)

Country Link
US (3) US10160799B2 (it)
EP (2) EP3221349B1 (it)
JP (3) JP6830061B2 (it)
KR (1) KR20170126855A (it)
CN (1) CN107428820B (it)
AU (2) AU2015348012B2 (it)
BR (1) BR112017010498A2 (it)
CA (1) CA2966964A1 (it)
CY (1) CY1123746T1 (it)
DK (1) DK3221349T3 (it)
ES (1) ES2848376T3 (it)
HR (1) HRP20210124T1 (it)
HU (1) HUE053239T2 (it)
IL (2) IL251921B (it)
LT (1) LT3221349T (it)
MX (2) MX388142B (it)
PL (1) PL3221349T3 (it)
PT (1) PT3221349T (it)
RS (1) RS61431B1 (it)
RU (2) RU2020126237A (it)
SG (1) SG11201703237VA (it)
SI (1) SI3221349T1 (it)
SM (1) SMT202100055T1 (it)
WO (1) WO2016079597A1 (it)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102313513B1 (ko) 2013-03-13 2021-10-15 프로테나 바이오사이언시즈 리미티드 Tau 면역치료제
JP6401871B2 (ja) 2014-11-05 2018-10-10 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． パーキンソン病の治療のためのａａｄｃポリヌクレオチド
CN107428820B (zh) * 2014-11-19 2022-03-22 阿克松神经系统科学公司 在阿尔茨海默氏病中的人源化tau抗体
KR102471787B1 (ko) * 2016-05-02 2022-11-29 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
US10752679B2 (en) 2016-05-02 2020-08-25 Prothena Biosciences Limited Tau immunotherapy
CU24538B1 (es) * 2016-05-02 2021-08-06 Prothena Biosciences Ltd Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 16g7
MA47499A (fr) 2017-02-17 2019-12-25 Denali Therapeutics Inc Anticorps anti-tau et leurs procédés d'utilisation
CA3056517A1 (en) * 2017-03-28 2018-10-04 Janssen Vaccines & Prevention B.V. Binding molecules that specifically bind to tau
SG11201910066QA (en) 2017-05-02 2019-11-28 Prothena Biosciences Ltd Antibodies recognizing tau
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2019048017A1 (en) * 2017-09-07 2019-03-14 Danmarks Tekniske Universitet METHODS FOR REMOVING NOX FROM A GAS STREAM CONTAINING MORE THAN ONE GAS COMPOUND
TWI853617B (zh) 2017-10-16 2024-08-21 日商衛材R&D企管股份有限公司 抗tau抗體及其用途
MX386373B (es) 2018-02-01 2025-03-18 Nkmax Co Ltd Método para producir células asesinas naturales (nk) y composición para el tratamiento de cáncer.
WO2019161384A1 (en) * 2018-02-19 2019-08-22 New York University Tau single domain antibodies
WO2019186276A2 (en) 2018-03-28 2019-10-03 Axon Neuroscience Se Antibody-based methods of detecting and treating alzheimer's disease
KR102787585B1 (ko) * 2018-05-03 2025-03-27 워싱턴 유니버시티 부위-특이적 타우 인산화에 기반한 진단 및 치료 방법
BR112020023082A2 (pt) 2018-05-15 2021-02-09 Voyager Therapeutics, Inc. composições e métodos para o tratamento de doença de parkinson
US20210347869A1 (en) * 2018-10-17 2021-11-11 The University Of Queensland Methods and compositions for treating tauopathies
US20220153821A1 (en) * 2018-11-08 2022-05-19 Prothena Biosciences Limited Antibodies recognizing tau
WO2020180819A1 (en) * 2019-03-03 2020-09-10 Prothena Biosciences Limited Antibodies recognizing tau
TWI877179B (zh) * 2019-06-27 2025-03-21 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
WO2021030615A1 (en) * 2019-08-13 2021-02-18 Washington University Methods to detect mtbr tau isoforms and use thereof
MX2022002852A (es) 2019-09-09 2022-03-25 Axon Neuroscience Se Biomarcadores y tratamientos de la enfermedad de alzheimer y deterioro cognitivo leve.
WO2021119400A1 (en) * 2019-12-12 2021-06-17 Alector Llc Methods of use of anti-cd33 antibodies
WO2021173962A1 (en) * 2020-02-28 2021-09-02 Genemo, Inc. Methods and materials for diagnosis and treatment of neuronal disorder
CA3185040A1 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
CA3192987A1 (en) * 2020-09-22 2022-03-31 Kathleen E. Clarence-Smith Pharmaceutical combination for the treatment of human hypocholinergic disorders
CN112625129B (zh) * 2020-11-26 2022-05-20 江苏荃信生物医药股份有限公司 一种抗人白介素23及包含其的试剂盒及其检测方法
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2024036005A1 (en) * 2022-08-10 2024-02-15 Nkmax Co., Ltd. Method of treating alzheimer's disease with expanded natural killer cells
EP4587470A1 (en) 2022-09-15 2025-07-23 Voyager Therapeutics, Inc. Tau binding compounds
ES2998138R1 (es) * 2023-07-28 2025-04-30 Novartis Ag Nuevos usos del omalizumab
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HU196394B (en) 1986-06-27 1988-11-28 Richter Gedeon Vegyeszet Process for preparing 2-halogenated ergoline derivatives
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
FI102355B1 (fi) 1988-02-11 1998-11-30 Bristol Myers Squibb Co Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DE69328430T2 (de) 1992-07-27 2001-01-25 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Zielgerichte liposome zur blut-hirne schranke
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CA2142190C (fr) 1995-02-14 1998-01-27 Marc Lessard Conduite d'exfiltration d'air use
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
DK1516628T3 (da) 1995-07-27 2013-09-08 Genentech Inc Stabil, isotonisk lyofiliseret proteinformulering
EP0871490B1 (en) 1995-12-22 2003-03-19 Bristol-Myers Squibb Company Branched hydrazone linkers
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
PT994728E (pt) 1997-04-09 2008-11-11 Intellect Neurosciences Inc Anticorpos recombinantes específicos contra terminações beta-amilóide, codificação por adn e métodos de utilização destes
ATE319745T1 (de) 1997-05-21 2006-03-15 Biovation Ltd Verfahren zur herstellung von nicht-immunogenen proteinen
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP2002510481A (ja) 1998-04-02 2002-04-09 ジェネンテック・インコーポレーテッド 抗体変異体及びその断片
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
CN1237076C (zh) 1999-01-15 2006-01-18 杰南技术公司 具有改变的效应功能的多肽变体
WO2001018546A2 (en) 1999-09-09 2001-03-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Screening for inhibitors of 'paired helical filaments'
PL210157B1 (pl) 2000-02-24 2011-12-30 Lilly Co Eli Humanizowane przeciwciało lub jego fragment, kwas polinukleinowy, wektor ekspresyjny do ekspresji przeciwciała lub jego fragmentu, komórka transfekowana wektorem ekspresyjnym, kompozycja farmaceutyczna i zastosowanie humanizowanego przeciwciała lub jego fragmentu do leczenia choroby Alzheimera
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
WO2002017930A2 (en) 2000-08-30 2002-03-07 The Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
ATE445838T1 (de) 2001-07-25 2009-10-15 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
MXPA04001072A (es) 2001-08-03 2005-02-17 Glycart Biotechnology Ag Variantes de glicosilacion de anticuerpos que tienen citotoxicidad celulares dependiente de anticuerpos incrementada.
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
JP4414332B2 (ja) 2002-07-12 2010-02-10 アクソン・ニューロサイエンス・フォルシュングス−ウント・エントヴィックルングス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング アルツハイマーｔａｕタンパク質を発現するトランスジェニック動物
CA2802205C (en) 2002-07-31 2016-01-19 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
KR101186210B1 (ko) 2002-12-03 2012-10-08 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 혈뇌장벽을 통과하는 물질 수송용 인공 저밀도 지단백질 운반체
AU2003291910B2 (en) 2002-12-24 2009-10-01 Bellus Health (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
US20050089473A1 (en) 2003-09-10 2005-04-28 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier
SI2489364T1 (sl) 2003-11-06 2015-04-30 Seattle Genetics, Inc. Monometilvalinske spojine, konjugirane s protitelesi
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
HUE030079T2 (en) 2004-09-23 2017-04-28 Genentech Inc Cysteine-manipulated antibodies and conjugates
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
DK2625198T3 (en) * 2010-10-07 2015-09-28 Ac Immune Sa Antibodies that recognize the phosphorylated tau
MX345092B (es) * 2010-10-11 2017-01-17 Univ Zuerich Anticuerpos anti-tau humanos,.
MX391157B (es) 2011-09-19 2025-03-21 Axon Neuroscience Se Terapia basada en proteina y diagnostico de patologia mediada por tau en la enfermedad de alzheimer.
CA2869438C (en) * 2012-04-05 2021-08-17 Ac Immune S.A. Humanized tau antibody
SMT202000512T1 (it) * 2012-12-21 2021-01-05 Biogen Int Neuroscience Gmbh Anticorpi anti-tau umani
CN107428820B (zh) * 2014-11-19 2022-03-22 阿克松神经系统科学公司 在阿尔茨海默氏病中的人源化tau抗体

Also Published As

Publication number Publication date
RU2020126237A (ru) 2020-12-01
HUE053239T2 (hu) 2021-06-28
MX2021014367A (es) 2022-01-06
JP6864763B2 (ja) 2021-04-28
SG11201703237VA (en) 2017-06-29
PT3221349T (pt) 2021-01-21
AU2015348012A1 (en) 2017-05-18
RU2017120688A (ru) 2018-12-19
WO2016079597A1 (en) 2016-05-26
ES2848376T3 (es) 2021-08-09
CN107428820A (zh) 2017-12-01
MX388142B (es) 2025-03-19
JP2021119774A (ja) 2021-08-19
EP3221349A1 (en) 2017-09-27
EP3786182A1 (en) 2021-03-03
US20190169276A1 (en) 2019-06-06
AU2020227007B2 (en) 2024-05-30
IL251921B (en) 2021-07-29
LT3221349T (lt) 2021-02-10
IL284250A (en) 2021-07-29
SI3221349T1 (sl) 2021-02-26
IL251921A0 (en) 2017-06-29
RS61431B1 (sr) 2021-03-31
BR112017010498A2 (pt) 2017-12-26
CY1123746T1 (el) 2022-05-27
RU2017120688A3 (it) 2019-07-17
JP2018502558A (ja) 2018-02-01
US10160799B2 (en) 2018-12-25
RU2730668C2 (ru) 2020-08-24
AU2015348012B2 (en) 2020-07-02
US11319363B2 (en) 2022-05-03
AU2020227007A1 (en) 2020-09-17
US20210009666A1 (en) 2021-01-14
WO2016079597A8 (en) 2020-07-02
CN107428820B (zh) 2022-03-22
JP2020141669A (ja) 2020-09-10
CA2966964A1 (en) 2016-05-26
KR20170126855A (ko) 2017-11-20
US10745469B2 (en) 2020-08-18
JP6830061B2 (ja) 2021-02-17
US20180142007A1 (en) 2018-05-24
HK1244495A1 (en) 2018-08-10
HRP20210124T1 (hr) 2021-03-19
DK3221349T3 (da) 2021-01-04
PL3221349T3 (pl) 2021-05-17
MX2017006663A (es) 2017-08-21
EP3221349B1 (en) 2020-11-04

Similar Documents

Publication Publication Date Title
IL284250A (en) Tau antibodies of human origin in Alzheimer's disease
ZA201900373B (en) Anti-tim-3 antibodies
IL285722A (en) Methods for treating Alzheimer's disease
SG10201601719RA (en) Anti-LAG-3 Antibodies
GB201601073D0 (en) Antibodies
GB201621439D0 (en) IL-11Ra Antibodies
GB201610044D0 (en) Antibodies
IL252929A0 (en) Anti-acth antibodies from humans and their use
IL256097A (en) Antibody epitope
IL251837A0 (en) Anti-endoglin antibodies and their uses
GB201616699D0 (en) Antibodies
ZA201808317B (en) Anti-tnfrsf25 antibodies
GB201603291D0 (en) Antibodies
PT3101132T (pt) Anticorpo humano anti-transtirretina
GB201512596D0 (en) Biomolecules involved in Alzheimer's disease
PL3180356T3 (pl) Ludzkie przeciwciało anty-fgfr4
IL267271A (en) Antibodies against il-5
PT3484921T (pt) Anticorpos anti-il-22r
SG11201610594WA (en) Anti-il4-il 13 bispecific antibodies
SG11201703292VA (en) ANTI HUMAN Gas6 MONOCLONAL ANTIBODY
IL272676B (en) Bispecific antibodies against il-4 and il-13
GB201622197D0 (en) Antibodies
GB201414038D0 (en) Alzheimer's disease
GB201620414D0 (en) Antibodies
GB201615224D0 (en) Antibodies